Biodexa Pharmaceuticals (NASDAQ: BDRX) Stock on December 10, 2025: Violent Rally, Phase 3 FAP Progress and What 2026 Might Hold
Biodexa Pharmaceuticals (NASDAQ: BDRX) closed at $4.09 on December 9, down 53.5% from the prior session, after wild swings that saw the stock trade between $4.00 and $7.60 intraday. The company is advancing a Phase 3 trial in a rare inherited cancer syndrome and exploring new financing. Its float remains under 670,000 ADSs, fueling extreme volatility. Market cap stands near $5.5 million.